Vanguard Capital Management
GRCE

Vanguard Capital Management’s Grace Therapeutics GRCE Stock Holding History

Vanguard Capital Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$935K Buy
411,714
+10,058
+3% +$27.8K ﹤0.01% 3606
2026
Q1 		$1.86M Buy
+401,656
New +$1.58M ﹤0.01% 3393

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.23B AUM 74.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Vanguard Capital Management's GRCE Position: Q2 2026 in Review

Vanguard Capital Management increased its Grace Therapeutics (GRCE) stake by 2.5% in Q2 2026, buying an estimated $27.8K and bringing the position to 411,714 shares worth $935K. The position accounts for ﹤0.01% of the portfolio, ranked #3606.

Vanguard Capital Management first reported a position in GRCE in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.86M in Q1 2026. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

  • Vanguard Capital Management held 411,714 shares of Grace Therapeutics worth $935K as of Q2 2026.
  • Vanguard Capital Management bought 10,058 Grace Therapeutics shares in Q2 2026, an estimated $27.8K.
  • Grace Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3606 holding.
  • Vanguard Capital Management first reported a position in Grace Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Grace Therapeutics position peaked at $1.86M in Q1 2026.
  • 33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.